もう一度
トランスポゾン社社長の経歴をおさらいしましょう。
↓
Eckard was chairman of a number of companies until their successful exits including Peninsula Pharmaceuticals (sold to Johnson & Johnson, 2005), Cerexa (sold to Forest Laboratories, 2007), NovaCardia (sold to Merck, 2007), Calixa (sold to Cubist Pharmaceuticals, 2009) and Ocera Therapeutics (sold to Mallinckrodt, 2017). He was also a board member of Conforma Therapeutics (sold to Biogen-<span id="stockNameLink" data-stockcode="6652.T">IDEC</span>, 2006), Cabrellis Pharmaceuticals (sold to Pharmion, 2006) and Tobira Therapeutics (sold to Allergan, 2016).
もう一度
トランスポゾン社社長の経歴をおさらいしましょう。
↓
Eckard was chairman of a number of companies until their successful exits including Peninsula Pharmaceuticals (sold to Johnson & Johnson, 2005), Cerexa (sold to Forest Laboratories, 2007), NovaCardia (sold to Merck, 2007), Calixa (sold to Cubist Pharmaceuticals, 2009) and Ocera Therapeutics (sold to Mallinckrodt, 2017). He was also a board member of Conforma Therapeutics (sold to Biogen-<span id="stockNameLink" data-stockcode="6652.T">IDEC</span>, 2006), Cabrellis Pharmaceuticals (sold to Pharmion, 2006) and Tobira Therapeutics (sold to Allergan, 2016).